Tern Plc convertible loan note extended

Tern plc

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things (“IoT”) technology businesses, has announced that the maturity date of the Device Authority Limited Convertible Notes, as announced on 28 October 2022, has been extended to 31 December 2023 from 30 June 2023. Tern currently owns 53.8% of the Device Authority equity.

Capitalised terms used in this announcement shall, unless defined in this announcement or unless the context provides otherwise, bear the same meaning ascribed to such terms in the announcement made by the Company at 7.45 a.m. on 28 October 2022.

Tern plc is using its experience in pioneering leading-edge tech combined with a deep reach into expanding world markets to unlock the potential of UK companies who may be starting local, but are dreaming global.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern notes automotive momentum at Device Authority

Tern Plc notes that Device Authority, in which it holds a 25.3% stake, has announced further progress in the automotive sector, securing a new OEM customer and expanding an existing Tier 1 deployment.

Key management emerges as a delivery risk in automotive software

Key management is becoming a delivery-critical constraint in software-defined vehicles, influencing risk, compliance and programme scalability.

Pharma teams gain early insight into message effectiveness

Talking Medicines gives pharma teams early insight into which messages resonate with healthcare professionals.

Talking Medicines joins 2026 UK AI Index

Talking Medicines joins the UK AI Index 2026, confirming its growing role in data-driven healthcare strategy.

AI in Healthcare 2025

In 2025, AI began reshaping healthcare delivery and marketing with practical applications, signalling a maturing investment landscape.

Talking Medicines targets messaging risk in pharma brand strategy

Talking Medicines reduces messaging risk for pharma brands by measuring real-time HCP response.

Search

Search